Navigation Links
Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
Date:6/23/2008

Trial design and implementation pioneers from Cytel join peers in examining

the rise of adaptive study approaches and overcoming the remaining

challenges to wider adoption

CAMBRIDGE, Mass., June 23 /PRNewswire/ -- Cytel's renowned adaptive trial design and implementation experts Cyrus Mehta (http://www.cytel.com) and Judith Quinlan (http://www.cytel.com) will lead workshops and case study reviews at the Annual Meeting of the Drug Information Association (DIA) June 22 - 25, 2008 in Boston.

Adaptive trials are finding ever-increasing acceptance by sponsors and regulators seeking to improve clinical development productivity and reduce the rate of trial failures. Combining a wealth of experience designing and implementing adaptive trials together with over 20 years developing software for trial design, simulation and analysis, Cytel's clinical innovation know- how is unmatched.

At this year's DIA meeting, senior managers, clinicians, statisticians and trial logistics professionals from the biopharmaceutical industry will share their recent experiences with adaptive trials, and the insights gained on planning and conducting the next generation of adaptive studies.

Speaking on the latest innovative trial techniques and tools will be Cytel Co-Founder and President, Dr. Cyrus Mehta, and Vice President of Adaptive Trials, Judith Quinlan.

Dr. Mehta will join Dr. William Byrom, Vice President, Product Strategy at trial technology leader ClinPhone, for the workshop "Adaptive Design in Clinical Research", June 23, 10:30A - 12:30P.

Reporting on the PhRMA Working Group for Adaptive Trials efforts to chronicle trial innovation successes, Cytel's Judith Quinlan presents "Are You Ready for Adaptive Clinical Development? Examples, Case Studies, Successes" on June 24, 8:30A - 9:30A.
See the complete DIA meeting website

http://www.diahome.org/DIAHome/FlagshipMeetings/home.aspx?meetingid=14235

and the DIA's blog site

http://www.diaannual.com/

Dr. Mehta and Vice President Quinlan are available for interviews following the DIA conference.


'/>"/>
SOURCE Cytel, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):